ProShare Advisors LLC lifted its position in shares of Synopsys, Inc. (NASDAQ:SNPS) by 16.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 158,206 shares of the semiconductor company’s stock after purchasing an additional 22,083 shares during the period. ProShare Advisors LLC’s holdings in Synopsys were worth $41,013,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in the company. Profund Advisors LLC grew its holdings in shares of Synopsys by 3.3% during the fourth quarter. Profund Advisors LLC now owns 12,155 shares of the semiconductor company’s stock worth $3,151,000 after purchasing an additional 383 shares during the last quarter. Greenleaf Trust grew its holdings in shares of Synopsys by 2.2% during the fourth quarter. Greenleaf Trust now owns 4,623 shares of the semiconductor company’s stock worth $1,198,000 after purchasing an additional 100 shares during the last quarter. CIBC World Markets Inc. grew its holdings in shares of Synopsys by 9.8% during the fourth quarter. CIBC World Markets Inc. now owns 17,224 shares of the semiconductor company’s stock worth $4,465,000 after purchasing an additional 1,540 shares during the last quarter. Vident Investment Advisory LLC grew its holdings in shares of Synopsys by 12.2% during the fourth quarter. Vident Investment Advisory LLC now owns 2,832 shares of the semiconductor company’s stock worth $733,000 after purchasing an additional 309 shares during the last quarter. Finally, FDx Advisors Inc. grew its holdings in shares of Synopsys by 3.0% during the fourth quarter. FDx Advisors Inc. now owns 2,341 shares of the semiconductor company’s stock worth $607,000 after purchasing an additional 68 shares during the last quarter. Institutional investors own 86.11% of the company’s stock.
Several research firms have recently weighed in on SNPS. Wells Fargo & Company boosted their price target on Synopsys from $285.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, February 10th. KeyCorp upped their target price on Synopsys from $290.00 to $315.00 and gave the company an “overweight” rating in a report on Tuesday, February 16th. Royal Bank of Canada upped their target price on Synopsys from $250.00 to $330.00 and gave the company an “outperform” rating in a report on Tuesday, February 16th. Zacks Investment Research cut Synopsys from a “hold” rating to a “strong sell” rating and set a $224.00 target price on the stock. in a report on Tuesday, February 2nd. Finally, Bank of America cut Synopsys from a “buy” rating to a “neutral” rating in a report on Monday, January 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. Synopsys has a consensus rating of “Buy” and a consensus target price of $279.33.
In other news, Director Steven Walske sold 9,845 shares of the company’s stock in a transaction that occurred on Wednesday, December 16th. The stock was sold at an average price of $248.03, for a total transaction of $2,441,855.35. Following the transaction, the director now directly owns 2,784 shares of the company’s stock, valued at $690,515.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Trac Pham sold 10,000 shares of the stock in a transaction on Monday, December 21st. The shares were sold at an average price of $254.00, for a total value of $2,540,000.00. Following the completion of the sale, the chief financial officer now directly owns 28,174 shares of the company’s stock, valued at $7,156,196. The disclosure for this sale can be found here. Insiders have sold 38,946 shares of company stock worth $10,045,490 over the last ninety days. 1.84% of the stock is owned by insiders.
Synopsys stock opened at $254.69 on Tuesday. The stock has a market capitalization of $38.98 billion, a price-to-earnings ratio of 59.79, a PEG ratio of 5.07 and a beta of 1.10. Synopsys, Inc. has a 52-week low of $104.90 and a 52-week high of $300.91. The stock’s 50 day moving average price is $268.10 and its two-hundred day moving average price is $233.88. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.10 and a current ratio of 1.19.
Synopsys (NASDAQ:SNPS) last issued its earnings results on Wednesday, February 17th. The semiconductor company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.07 by $0.45. Synopsys had a return on equity of 14.81% and a net margin of 18.03%. During the same quarter last year, the business earned $1.01 EPS. On average, equities research analysts forecast that Synopsys, Inc. will post 4.41 EPS for the current year.
Synopsys, Inc provides electronic design automation software products used to design and test integrated circuits. It offers Fusion Design Platform, a digital design implementation solution; Verification Continuum Platform that provides virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions.
See Also: Float
Want to see what other hedge funds are holding SNPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synopsys, Inc. (NASDAQ:SNPS).
Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.